Vlado Perkovic's Publications

• Barriers to Care: New Medications and CKD

  Journal articles

  2024

  Kidney International Reports

• Targeting APRIL in the Treatment of IgA Nephropathy

  Journal articles

  2024

  Clinical Journal of the American Society of Nephrology

• Kidney Function, Albuminuria, and Risk of Incident Atrial Fibrillation: A Systematic Review and Meta-Analysis

  Journal articles

  2024

  American Journal of Kidney Diseases

• Hypoglycemia and Cardiovascular Outcomes in the CARMELINA and CAROLINA Trials of Linagliptin A Secondary Analysis of Randomized Clinical Trials

  Journal articles

  2024

  JAMA Cardiology

• Primary and Secondary Cardiovascular and Kidney Prevention With Canagliflozin: Insights From the CANVAS Program and CREDENCE Trial

  Journal articles

  2024

  Journal of the American Heart Association

• Estimated Lifetime Cardiovascular, Kidney, and Mortality Benefits of Combination Treatment With SGLT2 Inhibitors, GLP-1 Receptor Agonists, and Nonsteroidal MRA Compared With Conventional Care in Patients With Type 2 Diabetes and Albuminuria

  Journal articles

  2024

  Circulation

• Estimating the population-level impacts of improved uptake of SGLT2 inhibitors in patients with chronic kidney disease: a cross-sectional observational study using routinely collected Australian primary care data

  Journal articles

  2024

  The Lancet Regional Health - Western Pacific

• The Prevalence of CKD in Australian Primary Care: Analysis of a National General Practice Dataset

  Journal articles

  2024

  Kidney International Reports

• Timing of statistical benefit of canagliflozin in patients with type 2 diabetes for cardiovascular and heart failure outcomes: Insights from the CANVAS Program and CREDENCE trial

  Journal articles

  2024

  Diabetes, Obesity and Metabolism

• Selonsertib in Patients with Diabetic Kidney Disease: A Phase 2b Randomized Active Run-In Clinical Trial

  Journal articles

  2024

  Journal of the American Society of Nephrology

• Effect of Ziltivekimab on Determinants of Hemoglobin in Patients with CKD Stage 3-5: An Analysis of a Randomized Trial (RESCUE)

  Journal articles

  2024

  Journal of the American Society of Nephrology

• The Point-of-Care Peritoneal Dialysis System Early Evaluation Study (POC-PDEE): A pilot proof-of-principal study of the Ellen Medical Devices Point-of-Care affordable peritoneal dialysis system

  Journal articles

  2024

  Peritoneal Dialysis International

• Results of a randomized double-blind placebo-controlled Phase 2 study propose iptacopan as an alternative complement pathway inhibitor for IgA nephropathy

  Journal articles

  2024

  Kidney International

• Combination therapy with kidney protective therapies: Optimizing the benefits?

  Journal articles

  2024

  Current Opinion in Nephrology and Hypertension

• Safety and Efficacy of Iptacopan in Patients with IgA Nephropathy with Baseline eGFR 20 to <30 mLmin: Phase 3 APPLAUSE-IgAN Subcohort Results

  Journal articles

  2024

  Journal of the American Society of Nephrology

• Effect of Iptacopan on Proteinuria and Complement Biomarkers in IgAN: Interim Analysis of the Phase 3 APPLAUSE-IgAN Study

  Journal articles

  2024

  Journal of the American Society of Nephrology

• Semaglutide Reduced Risks of Major Kidney Outcomes Irrespective of CKD Severity in the FLOW Trial

  Journal articles

  2024

  Journal of the American Society of Nephrology

• Effect of Semaglutide on Mortality Outcomes in the FLOW Trial

  Journal articles

  2024

  Journal of the American Society of Nephrology

• Prognostic Enrichment Using the Klinrisk Model: Insights from Landmark Kidney Disease Clinical Trials

  Journal articles

  2024

  Journal of the American Society of Nephrology

• Risk-Based Implementation of SGLT2 Inhibitors: Insights from the CANVAS Program and CREDENCE Trial

  Journal articles

  2024

  Journal of the American Society of Nephrology

• Cardiovascular, Kidney, and Safety Outcomes with Canagliflozin in Older Adults: A Pooled Secondary Analysis of the CANVAS Program and CREDENCE Trial

  Journal articles

  2024

  Journal of the American Society of Nephrology

• Assessing the Quality of Care for People with CKD: A Systematic Review and Meta-Analysis

  Journal articles

  2024

  Journal of the American Society of Nephrology

• Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors in Kidney Disease.

  Journal articles

  2024

  NEJM Evid

• The Effects of Anti-Inflammatory Agents on Cardiovascular Outcomes: A Systematic Review and Meta-Analysis of Randomised Controlled Clinical Trials

  Journal articles

  2024

  Heart, Lung and Circulation

• WCN24-1837 BEYOND: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBOCONTROLLED TRIAL OF ZIGAKIBART IN ADULTS WITH IGA NEPHROPATHY

  Journal articles

  2024

  Kidney International Reports

• WCN24-1506 EFFICACY AND SAFETY OF IPTACOPAN IN PATIENTS WITH IgA NEPHROPATHY: INTERIM RESULTS FROM THE PHASE 3 APPLAUSE-IgAN STUDY

  Journal articles

  2024

  Kidney International Reports